More transparent pricing would allow patients and families to make better decisions, but there are limitations to how reliably it promotes efficiency and market discipline.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
Dr Daphne Mlachila joins Ethics Talk to discuss her article: “How Should Clinicians and Researchers in Government Respond to Threats to Their Offices?”
Isabelle M. Mikell joins Ethics Talk to discuss her article, coauthored with Courtney L. Savage Hoggard and Dr Harald Schmidt: "What Should Be Roles of Federal Clinician Governors in Motivating Equity in Locally Coordinated Triage Protocols?"
Dr Isabelle Freiling joins Ethics Talk to discuss her article, coauthored with Nicole M. Krause and Dr Dietram A. Scheufele: “Science and Ethics of ‘Curing’ Misinformation.”